Sun Pharma restructures senior management: Kal Sundaram, Kirti Ganorkar, Aalok Shanghvi get new responsibilities

Announcing changes during an earnings call on the first-quarter results, Sun Pharma Managing Director Dilip Shanghvi said Kirti Ganorkar, who was heading the global business development function, will now head the India formulations business.

New Delhi: Sun Pharmaceutical Industries on Tuesday announced senior management rejig, with India and emerging markets head Kal Sundaram will now be responsible for Japan and China businesses besides the company's strategic initiatives.

Announcing changes during an earnings call on the first-quarter results, Sun Pharma Managing Director Dilip Shanghvi said Kirti Ganorkar, who was heading the global business development function, will now head the India formulations business.

Read Also: Sun Pharma sudden closure of Vadodara RnD units leaves around 85 employees in lurch

Further, Aalok Shanghvi -- who is currently Senior VP - Emerging Markets & Global R&D -- will have additional responsibility for generic business development in addition to his current role.

Read Also: Sun Pharma to ramp up global speciality business; eyes “low-to-mid teens” growth in revenues for FY20

"We will look for fresh recruitment for the branded business development function...," Shanghvi said.

Read Also: Sun Pharma unveils Ezallor Sprinkle capsules for treating lipid disorder in US